0
0

Protecting America’s Life Saving Medicines Act of 2019

10/28/2022, 1:45 AM

Congressional Summary of HR 5402

Protecting America's Life Saving Medicines Act of 2019

This bill directs the Food and Drug Administration (FDA) to conduct a study on drugs that are currently being tested and are unlikely to be approved, but would, if approved, address an unmet medical need for the treatment of a serious or life threatening disease or condition or a rare disease or condition (high-risk, high-reward drugs). The FDA must submit to the Department of the Treasury a list of such high-risk, high-reward drugs not later than 180 days after the completion of the study.

The bill also allows a new tax credit for 25% of the clinical testing expenses for high-risk, high-reward drugs.

Current Status of Bill HR 5402

Bill HR 5402 is currently in the status of Bill Introduced since December 11, 2019. Bill HR 5402 was introduced during Congress 116 and was introduced to the House on December 11, 2019.  Bill HR 5402's most recent activity was Referred to the Subcommittee on Health. as of December 12, 2019

Bipartisan Support of Bill HR 5402

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
2
Democrat Cosponsors
0
Republican Cosponsors
2
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 5402

Primary Policy Focus

Taxation

Potential Impact Areas

- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Government studies and investigations
- Income tax credits
- Medical research

Alternate Title(s) of Bill HR 5402

Protecting America’s Life Saving Medicines Act of 2019
To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to conduct a study on high-risk, high-reward drugs, and for other purposes.
Protecting America’s Life Saving Medicines Act of 2019

Comments